III期非小细胞肺癌根治性放化疗期间kV-CBCT显示的原发肿瘤体积变化的预后价值
本研究回顾性分析52例接受根治性放化疗的局部晚期非小细胞肺癌患者,利用kV-CBCT在治疗期间四个时间点勾画原发肿瘤大体体积。结果显示放疗早期即出现显著肿瘤体积缩小,且体积缩小程度与疾病控制和总生存改善相关,提示kV-CBCT有潜力作为实用的预后影像标志物。
要点
- 根治性放化疗期间原发肿瘤体积在放疗早期即显著缩小。
- 第1至第21次分次间相对体积缩小越多,远处控制与总生存越好。
- kV-CBCT有潜力作为实用的预后影像标志物。
核心结论
- 局部晚期非小细胞肺癌根治性放化疗期间原发肿瘤体积在放疗早期即发生显著缩小。
- 治疗期间相对肿瘤体积缩小越多与疾病控制和总生存改善相关。
- kV-CBCT有潜力作为实用的预后影像标志物。
研究设计与样本
- 回顾性分析52例接受根治性放化疗的局部晚期非小细胞肺癌患者。
- 使用kV-CBCT图像在治疗期间四个时间点勾画原发肿瘤大体体积。
- 根据各时间点绝对和相对体积变化对患者进行二分法分组。
- 进行统计分析以评估体积变化与临床结局之间的相关性。
主要发现
- 第1、11、21次分次及末次分次的中位大体肿瘤体积分别为77.1、48.3、42.5和29.9 cm3。
- 第1至第21次分次间相对体积缩小越多与远处控制改善相关(HR=0.35,95%CI:0.13-0.94,p=0.038)。
- 第1至第21次分次间相对体积缩小越多与总生存改善相关(HR=0.40,95%CI:0.16-0.98,p=0.046)。
- 第11至第21次分次间相对体积缩小越多与无进展生存改善相关(HR=0.39,95%CI:0.17-0.88,p=0.02),总生存有改善趋势(HR=0.43,95%CI:0.17-1.06,p=0.07)。
- 多因素分析中,第11至第21次分次间相对体积缩小越多与无进展生存改善(HR=0.39,95%CI:0.16-0.97,p=0.041)和总生存改善(HR=0.31,95%CI:0.11-0.88,p=0.027)相关。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Kilovoltge cone beam computed tomography (kV-CBCT) allows for tumor localization and response assessment during definitive chemoradiotherapy for locally advanced NSCLC. We hypothesize that significant tumor volume loss occurs early during radiotherapy and that the extent of volume loss correlates with clinical outcomes. METHODS: A total of 52 patients with locally advanced NSCLC treated with definitive chemoradiotherapy were reviewed. kV-CBCT images were used to contour primary gross tumor volumes at four time points during treatment. Patients were dichotomized according to absolute and relative volume changes at each time point. Statistical analyses were performed to evaluate correlations between volume changes and clinical outcomes. RESULTS: The median gross tumor volumes were 77.1, 48.3, 42.5, and 29.9 cm3 for fractions 1, 11, 21, and final, respectively. Greater relative volume loss between fractions 1 and 21 correlated with improved distant control (hazard ratio [HR] = 0.35, 95% confidence interval [CI]: 0.13-0.94, p = 0.038) and overall survival (HR = 0.40, 95% CI: 0.16-0.98, p = 0.046). Greater relative volume loss between fractions 11 and 21 correlated with improved progression-free survival (HR = 0.39, 95% CI: 0.17-0.88, p = 0.02) and trended toward improved overall survival (HR = 0.43, 95% CI: 0.17-1.06, p = 0.07). On multivariate analysis, greater relative volume loss between fractions 11 and 21 correlated with improved progression-free survival (HR = 0.39, 95% CI: 0.16-0.97, p = 0.041) and overall survival (HR = 0.31, 95% CI: 0.11-0.88, p = 0.027). CONCLUSIONS: Significant primary tumor volume loss occurs early during radiotherapy for locally advanced NSCLC. Greater relative tumor volume loss during treatment correlates with improved disease control and overall survival. Thus, kV-CBCT has potential to be used as a practical prognostic imaging marker.
引用
- Wald P, Mo X, Barney C, et al. Prognostic Value of Primary Tumor Volume Changes on kV-CBCT during Definitive Chemoradiotherapy for Stage III Non-Small Cell Lung Cancer. J Thorac Oncol. 2017. PMID: 28843360. doi:10.1016/j.jtho.2017.08.010
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。